These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23478050)

  • 1. Cardiac biomarkers in persons with HIV infection: a review of the literature.
    Chandler C; Dorsen C
    J Assoc Nurses AIDS Care; 2014; 25(1):83-91. PubMed ID: 23478050
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment: risks of cardiovascular disease in HIV--perspective needed.
    Wanke C
    AIDS Read; 2004 Feb; 14(2):94-5. PubMed ID: 14997865
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on cardiovascular complications in HIV infection.
    Currier JS
    Top HIV Med; 2009; 17(3):98-103. PubMed ID: 19675367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased cardiovascular risk in HIV infection: drugs, virus and immunity.
    Murphy R; Costagliola D
    AIDS; 2008 Aug; 22(13):1625-7. PubMed ID: 18670222
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of biomarkers in predicting CVD risk in the setting of HIV infection?
    Worm SW; Hsue P
    Curr Opin HIV AIDS; 2010 Nov; 5(6):467-72. PubMed ID: 20978389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score.
    Mangili A; Gerrior J; Tang AM; O'Leary DH; Polak JK; Schaefer EJ; Gorbach SL; Wanke CA
    Clin Infect Dis; 2006 Dec; 43(11):1482-9. PubMed ID: 17083026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating and managing cardiovascular disease risk factors in HIV-infected patients.
    Top HIV Med; 2010 Dec; 18(5):164-8. PubMed ID: 21245517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Disease and HIV Infection.
    Klein D; Hurley LB; Sidney S
    N Engl J Med; 2003 Nov; 349(19):1869-70; author reply 1869-70. PubMed ID: 14602888
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients.
    Fisher SD; Kanda BS; Miller TL; Lipshultz SE
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):383-94. PubMed ID: 22149317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
    Patel P; Bush T; Overton T; Baker J; Hammer J; Kojic E; Conley L; Henry K; Brooks JT;
    Antivir Ther; 2012; 17(4):755-61. PubMed ID: 22301072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes mellitus, cardiovascular risk, and HIV disease.
    Grinspoon S
    Circulation; 2009 Feb; 119(6):770-2. PubMed ID: 19221228
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular risk factors and antiretroviral therapy.
    Kuritzkes DR; Currier J
    N Engl J Med; 2003 Feb; 348(8):679-80. PubMed ID: 12594310
    [No Abstract]   [Full Text] [Related]  

  • 15. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.
    Masiá M; Bernal E; Padilla S; García N; Escribano JC; Martínez E; Gutiérrez F
    J Antimicrob Chemother; 2009 Sep; 64(3):589-98. PubMed ID: 19625372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial and platelet function alterations in HIV-infected patients.
    Gresele P; Falcinelli E; Sebastiano M; Baldelli F
    Thromb Res; 2012 Mar; 129(3):301-8. PubMed ID: 22192157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART.
    Berg T; Zdunek D; Stalke J; Dupke S; Baumgarten A; Carganico A; Hess G
    Eur J Med Res; 2007 Apr; 12(4):152-60. PubMed ID: 17509959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection.
    Lichtfuss GF; Hoy J; Rajasuriar R; Kramski M; Crowe SM; Lewin SR
    Biomark Med; 2011 Apr; 5(2):171-86. PubMed ID: 21473720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.
    Schafer JJ; Short WR; Squires KE
    Pharmacotherapy; 2010 Oct; 30(10):1072-83. PubMed ID: 20874044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.